Ontario's clinical practice guidelines for neonatal abstinence syndrome (NAS) provide
evidence-informed recommendations that address the needs of substance using pregnant …

A bstract Neonatal abstinence syndrome (NAS) from in utero opioid exposure has reached
epidemic levels in the United States. Although nonpharmacologic therapies form the …

OBJECTIVE To survey current practices for the treatment of neonatal abstinence syndrome
(NAS) among institutions in the United States to identify changes in national practice over …

Neonatal abstinence syndrome (NAS) secondary to in-utero opioid exposure is an
increasing problem. Variability in assessment and treatment of NAS has been attributed to …

Neonatal abstinence syndrome (NAS) was first described in the 1970s, identified among
neonates whose mothers most commonly used heroin or were on methadone maintenance …

Despite the growing knowledge of recognition, treatment, and outcomes, NAS continues to
challenge clinicians. An increasing number of women receiving prescribed medications for …

Neonatal abstinence syndrome (NAS) is a postnatal drug withdrawal syndrome in newborns
caused primarily by in utero exposure to opioids. In the United States, the incidence of NAS …

Neonatal abstinence syndrome (NAS) results from discontinuation of in utero exposures to
opioids/substances. The rising incidence of NAS has prompted an increased need for …

Background Neonatal abstinence syndrome (NAS) occurs following prenatal opioid
exposure. It is characterized by signs and symptoms indicating central nervous system …

Neonatal abstinence syndrome (NAS) is a result of the sudden discontinuation of fetal
exposure to substances that were used or abused by the mother during pregnancy …